Zhitong Finance App learned that Moderna Inc. (MRNA.US) and MRK.US (MRK.US) announced that their personalized cancer vaccine successfully reduced the risk of melanoma recurrence in a large-scale late-stage trial, marking an important milestone in cancer therapy based on mRNA technology. The trial reached the main end — data showed that the vaccine in combination with MSD's immunization drug Keytruda can reduce the recurrence rate of melanoma compared to using Keytruda alone. The two companies said in a statement on Wednesday that the study simultaneously reached a critical secondary end, which is to prove that the vaccine helps prevent the spread of tumors to other parts of the body.

Zhitong Finance App learned that Moderna Inc. (MRNA.US) and MRK.US (MRK.US) announced that their personalized cancer vaccine successfully reduced the risk of melanoma recurrence in a large-scale late-stage trial, marking an important milestone in cancer therapy based on mRNA technology. The trial reached the main end — data showed that the vaccine in combination with MSD's immunization drug Keytruda can reduce the recurrence rate of melanoma compared to using Keytruda alone. The two companies said in a statement on Wednesday that the study simultaneously reached a critical secondary end, which is to prove that the vaccine helps prevent the spread of tumors to other parts of the body.